Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates
Small-sample open-label human bioavailability study without a placebo control — mechanistic, not efficacy.
Hydrolysed collagen contains enzymatically fragmented collagen proteins. Digestion releases amino acids and a subset of hydroxyproline-containing peptides detectable in human blood. Clinical effects depend on peptide preparation, dose, comparator and outcome; skin trials conflict when funding and trial quality are considered, while joint and tendon studies mix distinct collagen forms or training protocols.
Small-sample open-label human bioavailability study without a placebo control — mechanistic, not efficacy.
Very small single-blind human crossover comparing peptide profiles across three collagen sources — mechanistic, hypothesis-generating for source-specific effects.
Small human single-blind crossover for plasma kinetics plus supportive murine tissue-distribution arm — mechanistic, industry-authored on a proprietary product.
Preclinical in-vitro digestion, intestinal-transport and hepatic first-pass model using HIEC-6 human intestinal epithelial cells and HepG2 hepatocytes. It measures peptide recovery and simulated bioavailability, not clinical efficacy or in-vivo human absorption.
Analytical laboratory study measuring amino acid content of bone broth vs commercial collagen supplements — comparative composition analysis, not a clinical outcome study.
Theoretical dietary modelling exercise using PDCAAS calculations — no human intervention, no biological outcomes, purely regulatory/reformulation reference.
Randomized human crossover pharmacokinetic study measuring absorption biomarkers rather than clinical outcomes.
Randomized double-blind four-treatment crossover pharmacokinetic pilot; N=6, only acute exposure and manufacturer-supplied hydrolysates, no functional clinical outcome or direct test of DoNotAge powder; absorption is not equivalent to clinical effect
Peer-reviewed narrative review of type I collagen structure, sources, extraction, physicochemical properties and applications. Useful as foundational biology and biomaterials background, but not a systematic review or clinical supplementation efficacy study.
12-month randomised controlled trial with DXA-verified BMD endpoints in postmenopausal osteopenic women — solid design but small sample (n = 39) and industry-funded/supplied.
Controlled in-vivo rat evidence directly measures bone mineral outcomes and identifies a high-dose renal safety signal, but provides no human efficacy evidence.
Meta-analysis of randomized trials of collagen alone or combined with calcium/vitamin D; High bone-outcome heterogeneity and mixing isolated collagen with calcium/vitamin D combinations. Trials do not prove fracture prevention, replace osteoporosis m
Non-controlled open-label follow-up observation with small sample and no placebo group — cannot isolate the collagen effect from natural history over the 4-year window.
Adequately powered 12-month randomised, double-blind, placebo-controlled phase III trial with objective DXA endpoints and supporting bone turnover biomarkers.
Small, short-duration pilot RCT (n=22, 4 weeks) explicitly designed to establish preliminary signal and feasibility rather than confirm clinical efficacy; surrogate blood biomarkers only, with no bone density or structural imaging outcomes.
Narrative (non-systematic) review of hydrolysed collagen extraction sources, molecular properties, and industrial/nutraceutical applications; provides mechanistic and background context rather than primary clinical outcome data, and summarises other primary studies without independent meta-analytic pooling.
Randomised, double-blinded, crossover trial with independent academic (non-industry) funding and no disclosed conflicts of interest, but the human cohort is very small (n=8) and the primary endpoints are mechanistic/surrogate (circulating amino acids, serum PINP, and an engineered-ligament tissue culture bioassay) rather than a clinical outcome. Tests gelatin plus vitamin C timed around exercise, not a standardised hydrolysed collagen peptide product, so it is included as a mechanism reference rather than direct clinical evidence.
Prospective open-label single-arm digital feasibility pilot following exploratory qualitative phase; No placebo/control group, high attrition (26/40), self-report outcomes, limited to women with BMI >25, tested Peptan 20 g not DoNotAge 10 g. Insuffic
Sourcedoi:10.2196/36339PMID 35639457PMC9198822 Trial registry
Randomized double-blind three-arm controlled clinical trial; Critically ill burn population, very high 40-g dose, short intervention, microbiome surrogates only. Not directly representative of healthy adults taking 10-g bovine collagen; cannot claim
Sourcedoi:10.1016/j.burns.2023.08.017PMID 38114377 Trial registry
Randomized, double-blind, placebo-controlled human trial in physically active adults with 24-week follow-up; evidence is clinically relevant but limited by substantial attrition/completer analysis and manufacturer funding.
Multicentre double-blind placebo-controlled 6-month RCT with n=250 in diagnosed knee OA — one of the largest and longest collagen-for-OA trials, though industry involvement present.
Peer-reviewed narrative review of preclinical and early clinical collagen-hydrolysate literature. It searched PubMed through May 2006 but also included congress abstracts and German-language literature based on author judgment, with no meta-analysis or formal risk-of-bias framework; therefore it is background synthesis rather than tier-1 efficacy evidence.
Meta-analysis of randomised placebo-controlled trials in humans — the top of the evidence hierarchy for the joint-comfort question, though limited by the small number of primary trials available.
Single, adequately powered (n=200) double-blind, placebo-controlled RCT with a statistically significant primary endpoint at 6 months but a non-significant result at 3 months, manufacturer funding tied to the tested product, and no benefit shown on validated joint-specific questionnaires.
Single randomised, double-blind, placebo-controlled phase II trial (n=60) with statistically significant but small-sample results and disclosed sponsor-linked financial interests. Tests native, undenatured chicken type II collagen via an oral-tolerance immune mechanism — a different ingredient and mechanism from the hydrolysed collagen peptides this site otherwise reviews.
Multicenter, randomised, double-blind, placebo- and active-comparator-controlled trial (n=191) with a 180-day intervention and pre-specified primary/secondary endpoints, but two of three authors are employees of the product's manufacturer and sponsor, a direct financial conflict of interest warranting tier-2 rather than tier-1. Tests undenatured type II collagen (UC-II) — a different ingredient, mechanism and dose scale (milligrams) from the hydrolysed collagen peptides (gram-scale) this site otherwise reviews.
Monocentric, prospective, randomised, double-blind, placebo-controlled phase III trial (n=139 completers of 160 randomised), fully funded by the tested product's manufacturer (GELITA Health GmbH), with pre-specified co-primary endpoints and Bonferroni-Holm correction for multiplicity.
Monocentric, prospective, randomised, double-blind, placebo-controlled trial (n=182 randomised, n=154 per-protocol analysed) in a general adult population — not restricted to physically active young adults — with hip and knee joint pain during ordinary daily activities, using Bonferroni-Holm-corrected co-primary endpoints assessed independently by both physician and participant.
Large randomised, double-blind, placebo-controlled trial (n=218 randomised; n=180 per-protocol) with pre-specified co-primary endpoints assessed by both participant and blinded physician, but the product was manufacturer-supplied and manufacturer-funded, one author has received GELITA-supported lecture fees, and another author joined the manufacturer-linked Collagen Research Institute after the study concluded.
This is a small (n=5/group), double-blinded, placebo-controlled animal (canine) study, not a human trial, using subjective owner/veterinarian pain-scoring rather than validated clinical instruments. Two co-authors are employees of the funding manufacturer. It tests undenatured type II collagen (UC-II) at a microgram dose via a proposed oral-tolerance mechanism in dogs — a fundamentally different ingredient, species, dose scale and mechanism from the hydrolysed collagen peptides this site otherwise reviews — and is included purely as a differentiation reference.
Randomized double-blind placebo-controlled trial, but very small and uses a multi-ingredient formula that prevents collagen-specific attribution.
Sourcedoi:10.1186/s12891-024-08244-wPMID 39755603PMC11699701 Trial registry
Double-blind randomized placebo-controlled trial, but very small and tests a multi-ingredient finished product, so effects cannot be attributed to hydrolysed collagen alone.
Four-arm randomized controlled study comparing collagen, calcium/vitamin D, their combination and placebo; Marine fish formulation, not bovine DoNotAge product. Multi-arm within-group findings should not be mistaken for placebo-adjusted effects; samp
Randomised double-blind placebo-controlled trial with DXA-measured body composition and objective muscle-strength testing in a clinically relevant sarcopenic population. Strong human design, but the 2025 corrigendum documents industry support: Gelita supplied the study product and covered participant-compensation and sample-analysis costs; a co-author was also a patent co-inventor.
Single double-blind, randomised, placebo-controlled RCT (n=25) with funding tied to the tested product's manufacturer via a closely affiliated research institute; the proteomic outcomes are exploratory/mechanistic rather than confirmatory clinical efficacy data.
Randomised, double-blinded, placebo-controlled trial (n=57 analysed) with a 12-week intervention, muscle biopsies and multiple objective outcome measures, but funded by an industry-affiliated research institute (Collagen Research Institute), a limiting factor for tier-1 status.
Randomised, double-blind, placebo-controlled trial (n=77 per-protocol) with a 12-week intervention and both per-protocol and intention-to-treat analyses, but the tested product is manufactured by Gelita AG and the paper's own funding disclosure is internally inconsistent (see funding field), which together limit this to tier-2.
Randomised, placebo-controlled, double-blind trial with objective DXA body composition and isometric strength endpoints; adequate sample per group with pre-specified power calculation.
Randomised, double-blind, parallel-group trial with gold-standard stable isotope tracer measurement of muscle protein synthesis (the direct mechanistic endpoint) in the target population.
Randomized placebo-controlled human trial with tissue biopsy outcomes, but small sample and partial industry funding.
Sourcedoi:10.3389/fphys.2026.1839695PMID 42376607PMC13310693
Double-blind randomized controlled feeding trial with deuterated water and muscle biopsies; Short mechanistic trial in older men and not a long-term strength outcome; does not exclude collagen's connective-tissue benefits. Research proteins were not
Sourcedoi:10.1016/j.ajcnut.2024.05.009PMID 38762187PMC11291473
Network meta-analysis of protein interventions plus resistance training; searched through May 2024; Indirect rankings and transitivity assumptions, very different population/training/supplement designs, small collagen nodes and no proof of direct bio
Randomized double-blind placebo-controlled tracer infusion and muscle biopsy study; Acute study, men only, no whey-only arm; product 83% whey. Public–private funded with GELITA involvement, and not a trial of collagen-alone efficacy.
Sourcedoi:10.1249/MSS.0000000000003596PMID 39501478PMC11801439
Systematic review focused on randomized evidence for Type I collagen hydrolysate, with useful formulation specificity but heterogeneous protocols and commercial ties.
Open-label, single-arm, single-centre trial with no placebo control — cannot separate treatment effect from natural history and behavioural change.
Double-blind randomized parallel placebo-controlled clinical trial in two university physical-medicine centers; Industry-linked authors associated with product supply; proprietary CollaSel PRO not the DoNotAge formulation; 8-week symptom outcomes wit
Sourcedoi:10.3390/jcm14113655PMID 40507417PMC12156922 Trial registry
Systematic review of RCTs through June 2023, RoB 2 and GRADE plus trial-sequential analysis; Combines mechanistically distinct hydrolysed collagen and undenatured type II collagen; results cannot be attributed wholly to DoNotAge's bovine hydrolysate.
Double-blind randomized placebo-controlled OA trial; Combination supplement, not isolated hydrolysed collagen; 68 people over 12 weeks. Does not disprove outcomes from other preparations or long-term trials.
Sourcedoi:10.1038/s41598-025-17505-0PMID 40897777PMC12405528
Narrative literature review of pooled human and epidemiological data on dietary oxalate; not itself a controlled trial and does not test collagen or collagen peptide intake directly.
Well-controlled academic study combining a large observational cohort (n=101) with a smaller controlled-diet crossover (n=11), with no industry funding or apparent conflicts of interest. Rated tier-3 rather than tier-1/2 because it studies general dietary protein intake — not hydrolysed collagen peptides specifically — and its endpoint (urinary oxalate/glycolate excretion) is a biochemical surrogate for kidney stone risk, not a clinical stone-formation outcome. Included as a background safety reference for readers considering higher-dose collagen peptide (i.e., concentrated protein) intake, alongside massey-2003-urinary-oxalate-kidney-stones.
This is an official EU regulatory scientific opinion by an independent expert panel, based on a manufacturer-submitted compositional and production-process dossier; the Panel concluded no toxicological studies were required given the nature of the novel food. It is not a primary clinical or preclinical research study, so it is rated below tier-1/2 despite its regulatory authority. It concerns egg membrane collagen peptides — a distinct raw material and product category (450–500 mg/day proposed dose) from the gram-scale hydrolysed bovine, porcine, marine or fish collagen peptides this site otherwise reviews — and is included as a differentiation and safety reference.
Single-blind four-arm parallel dose-ranging human trial; Free hydroxyproline is not equivalent to peptide-bound hydroxyproline in collagen powder; small study of healthy people with no stone-former cohort; manufacturer-funded.
Controlled-diet human feeding comparison of gelatin versus whey and gelatin dose challenges; Gelatin rather than a defined modern hydrolysed-collagen brand; high 30-g comparison; only 10 participants; urinary surrogate, not prospective ston
Individual randomised double-blind placebo-controlled trial with objective skin biomechanical endpoints, though single-centre, female-only, and industry-supplied product with Gelita-linked co-authors.
Individual randomised double-blind placebo-controlled trial with objective 3D wrinkle imaging plus suction-blister biomarker subgroup, though single-centre, female-only, and industry-supplied product with Gelita-linked co-authors.
Controlled, placebo-comparator, single-blind human trial in 72 women with objective skin endpoints. The Methods describe allocation by alternation rather than a concealed random sequence, so the study is better regarded as quasi-randomized/systematically allocated; the tested ELASTEN product was also a multi-ingredient formulation, limiting collagen-specific attribution.
Sourcedoi:10.3390/nu11102494PMID 31627309PMC6835901 Trial registry
Randomised double-blind placebo-controlled trial with objective skin elasticity + histological analysis in a substantial female sample — solid design but industry-funded and multi-ingredient product prevents isolating collagen effect.
Peer-reviewed systematic review that screened 9,057 records and included 10 publications, with a mechanistic focus on oral collagen and skin health. It did not perform a quantitative meta-analysis, and the small, heterogeneous, uniformly favorable evidence base limits certainty compared with pooled high-quality clinical evidence.
Randomised, double-blind, placebo-controlled trial with instrumental skin measurements in a modest but adequate sample of the target demographic.
Randomized double-blind placebo-controlled human trial with objective skin measurements, but the intervention combined collagen with glutathione and vitamin E, preventing collagen-specific attribution.
Randomized double-blind placebo-controlled human skin trial with objective outcomes, but small sample and substantial manufacturer-employee involvement.
Sourcedoi:10.1111/jocd.70565PMID 41311286PMC12661388 Trial registry
Three-arm randomized, double-blind, placebo-controlled human trial with objective skin measurements; industry co-funding and a combination formula limit ingredient-specific interpretation.
Sourcedoi:10.3390/nu16121908PMID 38931263PMC11206740 Trial registry
Double-blind randomized placebo-controlled human trial with instrumental skin outcomes, but manufacturer-funded and conducted by manufacturer employees.
In vitro cell-culture and three-dimensional lattice model using normal human fibroblasts; no human subjects, no oral supplementation, and no hydrolysed collagen peptides tested. Included as mechanistic background on vitamin C's cofactor role in collagen cross-linking, not as clinical evidence for any collagen peptide product.
Important 2023 synthesis of 26 skin RCTs (n=1,721) with risk-of-bias, source and duration analyses. Newer 2025–2026 syntheses and funding-sensitive subgroup results conflict, so this favorable pooled result is not definitive clinical proof.
Systematic review and random-effects meta-analysis of 19 RCTs (n=1,125) pooling skin hydration and elasticity outcomes for hydrolysed collagen supplementation, with formal risk-of-bias grading, sensitivity analysis, and a symmetrical funnel plot arguing against publication bias.
Systematic review and meta-analysis of 14 randomised, double-blind, placebo-controlled trials (n=967) following PRISMA and Cochrane Handbook methodology, with formal RoB-2 risk-of-bias assessment, funnel-plot publication-bias check, and pre-specified subgroup analyses by collagen source and supplementation duration.
Peer-reviewed narrative review summarising six clinical trials of oral hyaluronan for dry skin. Useful for historical context and dose mapping, but it is not a systematic review or meta-analysis and several primary studies involved Kewpie-affiliated investigators or products.
Randomised, double-blind, placebo-controlled trial (n=85) comparing two collagen hydrolysates of differing bioactive dipeptide content against placebo, with objective corneometry/cutometry/VisioFace SSA instrumentation and blood safety testing, but two of three authors are employees of the product manufacturer and the trial was conducted at a single site.
Narrative review (explicitly not a full systematic review; authors describe a rigid but non-exhaustive PubMed search restricted to indexed, high-impact journals) of preclinical studies and a small number of methodologically screened human RCTs on hydrolysed marine collagen and skin regeneration, published with funding from a company whose medical director is a co-author and markets a hydrolysed marine collagen supplement — a disclosed, direct commercial conflict of interest.
Randomised, double-blind, placebo-controlled human trial (n=40) with 12 weeks of oral hyaluronan and instrumental skin endpoints. Directly relevant to oral HA efficacy, but small and manufacturer-funded with three authors employed by Kewpie Corporation.
Two randomised, placebo-controlled clinical trials (pilot n=33; confirmatory n=101) plus ex vivo mechanistic work, with multiple objective instrumental endpoints (corneometry, high-resolution ultrasound, reflectance confocal microscopy), but two of four authors are employed by commercial entities with a direct interest in the tested collagen peptides and no formal funding/COI disclosure is provided in the article.
Umbrella review of published systematic reviews and meta-analyses; literature through March 6, 2025; Double counting of RCTs across included meta-analyses is possible. AMSTAR-2 distribution limits certainty; does not supersede the 2025 funding-sensit
Meta-analysis of 23 randomized controlled trials; prespecified subgroup analyses by funding and study quality; Subgroup results may have lower power; pooled interventions are heterogeneous and do not specifically test DoNotAge's finished bovine colla
PRISMA random-effects review; searched through January 1, 2026; PROSPERO CRD420261285731; Only 5 and 4 trials entered the two quantitative outcomes; risk-of-bias concerns, high heterogeneity, multi-ingredient formulations and frequent industry involv
Updated randomized-effects, multilevel and leave-one-out meta-analysis; searched through November 2025; Important heterogeneity and overlap with earlier syntheses. Several citations in the publisher bibliography show apparent incomplete DOI placehold
Sourcedoi:10.1111/jocd.71041
Systematic literature review with Cochrane RoB 2; searched through April 1, 2023; Search ends April 2023 despite 2026 publication, so not the latest primary-trial corpus. Descriptive vote-counting does not substitute for effect estimates. T
Systematic review and random-effects meta-analysis of training/supplementation RCTs; Most participants male; doses, training and vitamin C co-interventions varied; several small industry-specific formulation trials; cannot assume gains reflect myofib
Sourcedoi:10.1007/s40279-024-02079-0PMID 39060741PMC11561013
Double-blind randomized placebo-controlled 12-week resistance-training trial; Only 20 men, 30-g dose and vitamin C plus training. Not evidence that a 10-g generic powder prevents tendon injury or builds more muscle.
Systematic review of RCTs incorporating resistance/plyometric loading; Very small total sample and extreme male predominance; review authors' GRADE labels require cautious interpretation; not direct evidence for tendon-injury treatment or generic 10-
Systematic review with explicit human clinical eligibility and risk-of-bias discussion, but only six heterogeneous studies were included and overall certainty was judged low.
Triple-blind randomized training study in elite female Master athletes; Only 22 high-performance women; combined vitamin C and training, high 30-g dose; performance effect does not establish clinical tendon injury prevention.
Randomized placebo-controlled 14-week high-load knee-extensor training study; Selected branded peptide product, men only and exercise co-intervention; do not generalize low-dose effect to every collagen formulation.
Randomized pair-matched placebo-controlled pre-season training study; N=11 and confounded with concurrent high-intensity training and vitamin C; not evidence for reduced injury rates or a 10-g daily consumer dose.
Double-blind placebo-controlled randomized lower-body resistance training study; One selected proprietary peptide preparation, young male sample and specific program; negative result prevents a universal tendon-benefit claim but does not negate all c